Industry
Biotechnology
Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. Its product candidate includes Oral KORSUVA (difelikefalin), which has completed Phase II clinical trial to treat pruritus atopic dermatitis and pruritus non-dialysis-dependent chronic kidney disease (NDD-CKD) associated pruritus; and in Phase II clinical trial to treat pruritus chronic liver disease (CLD) primary biliary cholangitis (PBC) and notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.
Loading...
Open
0.35
Mkt cap
19M
Volume
1.4M
High
0.37
P/E Ratio
-0.15
52-wk high
1.31
Low
0.33
Div yield
N/A
52-wk low
0.24
Portfolio Pulse from Benzinga Insights
October 11, 2024 | 8:30 pm
Portfolio Pulse from Benzinga Insights
October 07, 2024 | 8:30 pm
Portfolio Pulse from Benzinga Insights
October 04, 2024 | 8:30 pm
Portfolio Pulse from Benzinga Insights
October 03, 2024 | 8:30 pm
Portfolio Pulse from Benzinga Insights
October 02, 2024 | 8:30 pm
Portfolio Pulse from Benzinga Insights
September 26, 2024 | 8:30 pm
Portfolio Pulse from Benzinga Insights
September 24, 2024 | 8:30 pm
Portfolio Pulse from Benzinga Insights
September 18, 2024 | 8:30 pm
Portfolio Pulse from Benzinga Insights
September 12, 2024 | 8:30 pm
Portfolio Pulse from Benzinga Insights
September 11, 2024 | 8:30 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.